Bispecific Antibody Production: Cell Line Strategies for Getting the Pairing Right
Bispecific antibodies have become one of the busiest areas in biologics. At least 15 now have FDA approval, including emicizumab, teclistamab, and faricimab. Bispecifics also featured in some of the highest-value antibody partnerships of early 2026. Yet bispecific antibody production remains harder than standard monoclonal antibody work.
The core challenge starts inside the cell. Therefore, the cell line strategy often decides whether a program scales.
Why Chain Mispairing Is the Core Problem
Many IgG-like bispecific antibodies use two different heavy chains and two light chains. If those chains pair randomly, cells can assemble 10 distinct species. In that scenario, only about one molecule in eight is the intended product. The rest are homodimers, half-antibodies, and mismatched light-chain variants.
Engineering Fixes That Start in the Sequence
Several formats reduce mispairing by design. For example, knobs-into-holes mutations favor heavy-chain heterodimers. Common light chain formats avoid light-chain mispairing entirely, and emicizumab uses one. Similarly, CrossMab domain swaps steer each light chain to its partner. Meanwhile, fragment formats such as BiTE molecules avoid some pairing issues. However, scFv-based designs can bring misfolding and aggregation risks.
Bispecific Antibody Production Depends on Chain Ratio
Even engineered formats need balanced expression. When one chain dominates, half-antibodies and homodimers increase. Consequently, vector design and chain ratio tuning are early priorities.
Transient expression helps compare formats quickly. Our comparison of CHO vs HEK293 vs Sf9 host cells explains those trade-offs. Next, stable CHO pools and clones need screening for correct assembly, not titer alone. Mass spectrometry and size exclusion chromatography help flag product-related impurities early.
Stability Testing Before Banking
Bispecific clones also need careful stability review. Over extended passages, expression balance between chains can shift. Therefore, track assembly quality, not just titer, across the full passage window. Our post on managing genetic drift explains why late-passage data matters. Once a clone holds steady, bank it before scale-up begins.
Why Upstream Purity Eases Downstream Work
Mispaired species often resemble the target closely. As a result, they can be difficult to remove with purification alone. A cleaner clone reduces the burden on purification and downstream processing. It also improves yield after polishing steps.
When evaluating a partner, ask how they measure correct assembly during clone screening. Also ask which formats they have expressed before. Finally, confirm they can move from transient material to stable pools without changing analytics.
Cell Culture Company offers cell line development, cell banking, and purification in one facility. That integration lets assembly data guide clone choices directly.
Frequently Asked Questions
Why is bispecific antibody production harder than monoclonal antibody production?
Cells must pair two different heavy chains and the correct light chains. Without engineering, random pairing produces many unwanted species that complicate purification.
Which host cells work best for bispecific antibody production?
CHO cells dominate commercial manufacturing. Meanwhile, HEK293 cells are common for rapid transient expression during early format screening.
